AlgoTx Announces “Last Patient Last Visit” in International Phase II Trial of ATX01 in Chemotherapy-Induced Peripheral Neuropathy PARIS, Sept. 24, 2024 (GLOBE NEWSWIRE) -- AlgoTherapeutix (AlgoTx), a clinical stage biotechnology company developing a first-in-class therapeutic for peripheral neuropathic pain, ATX01, announced...

AlgoTx Announces First Patients Dosed in US and European Arms of Phase II Clinical Trial of ATX01 in Rare Disease Erythromelalgia PARIS, Sept. 12, 2023 (GLOBE NEWSWIRE) --  AlgoTherapeutix (AlgoTx), a clinical stage biotechnology company developing targeted, first-in-class therapeutics for peripheral neuropathic pain,...